Medical authorities have issued an urgent safety alert affecting millions of Britons prescribed one of the UK's most commonly used antidepressants. The Medicines and Healthcare products Regulatory Agency (MHRA) has revealed a potentially serious side effect associated with sertraline that requires immediate medical attention.
What You Need to Know Immediately
The regulatory body has identified that sertraline, marketed under brand names including Lustral, can in rare cases cause a condition known as Secondary Intracranial Hypertension. This condition involves increased pressure around the brain that mimics symptoms of a brain tumour.
Critical Warning Signs to Watch For
Patients are being urged to contact their GP immediately if they experience any of the following symptoms while taking sertraline:
- Persistent headaches that don't respond to usual pain relief
- Vision problems including blurred vision, double vision or temporary vision loss
- Nausea and vomiting unrelated to other causes
- Ringing in the ears (tinnitus)
- Pain behind the eyes or when moving eyes
Why This Alert Matters Now
This warning comes after the MHRA reviewed numerous reports linking sertraline to this rare but serious condition. Dr Alison Cave, MHRA Chief Safety Officer, emphasised: "It's crucial that people taking sertraline don't stop their treatment abruptly, but should speak with their doctor if they have any concerns or experience these symptoms."
Understanding the Risk Level
While the condition remains rare, the potential severity warrants this nationwide alert. Sertraline is one of England's most prescribed antidepressants, with approximately 4.5 million patients receiving this medication last year alone.
What Patients Should Do Next
Medical professionals stress that patients should continue taking their medication as prescribed but remain vigilant for warning signs. Anyone experiencing the symptoms described should contact their GP or NHS 111 for immediate advice.
The MHRA continues to monitor the situation closely and advises healthcare professionals to report any suspected side effects through the Yellow Card scheme to help build better understanding of this medication's safety profile.
